Get startedLog in
    Picture of ALX Oncology Holdings logo

    ALXO — ALX Oncology Holdings News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    Brief: Alx Oncology Receives U.S. FDA Orphan Drug Designation For Gastric And Gastroesophageal Junction Cancer Treatment

    Picture of ALX Oncology Holdings logoALX Oncology Holdings
    27/01/2022 23:14
    Jan 27 (Reuters) - ALX Oncology Holdings Inc  ALXO.O :
    * ALX ONCOLOGY RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR
EVORPACEPT FOR THE TREATMENT OF PATIENTS WITH GASTRIC CANCER AND
GASTROESOPHAGEAL JUNCTION CANCER

Source text for Eikon:  ID:nGNX2kt37C 
Further company coverage:  ALXO.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ALX Oncology Holdings

    See all news